Comparative Effectiveness of 12 Treatment Strategies for Preventing Contrast-Induced Acute Kidney Injury: A Systematic Review and Bayesian Network Meta-analysis

American Journal of Kidney Diseases

Volumn 69, Issue 1, 2017, Pages 69-77

  Su, Xiaole ^a,b   Xie, Xinfang ^a   Liu, Lijun ^a   Lv, Jicheng ^a   Song, Fujian ^c   Perkovic, Vlado ^d   Zhang, Hong ^a  

^a PEKING UNIVERSITY FIRST HOSPITAL   (China)

^b SHANXI MEDICAL UNIVERSITY   (China)

^c UNIVERSITY OF EAST ANGLIA   (United Kingdom)

^d UNIVERSITY OF SYDNEY   (Australia)

Author keywords

acute kidney failure; AKI prevention; atorvastatin; cardiovascular events; contrast media; Contrast induced acute kidney injury (CI AKI); hydroxymethylglutaryl CoA reductase inhibitor; kidney disease; N acetylcysteine (NAC); rosuvastatin; serum creatinine; simvastatin; statin; statins; systematic review

Indexed keywords

ACETYLCYSTEINE; AMINOPHYLLINE; ASCORBIC ACID; ATRIAL NATRIURETIC FACTOR; ATRIAL NATRIURETIC FACTOR ALPHA; BICARBONATE; BRAIN NATRIURETIC PEPTIDE; CONTRAST MEDIUM; CREATININE; FENOLDOPAM; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ILOPROST; PROSTAGLANDIN; PROSTAGLANDIN E1; THEOPHYLLINE; THIOCTIC ACID; TOCOPHEROL;

ARTICLE; BAYES THEOREM; CLINICAL OUTCOME; COCHRANE LIBRARY; COMPARATIVE EFFECTIVENESS; CONTRAST INDUCED NEPHROPATHY; CREATININE CLEARANCE; DRUG DOSE REGIMEN; DRUG MEGADOSE; EMBASE; ESTIMATED GLOMERULAR FILTRATION RATE; FLUID THERAPY; HUMAN; LOW DRUG DOSE; MEDLINE; META ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; ACUTE KIDNEY INJURY; CHEMICALLY INDUCED; COMPARATIVE STUDY; NETWORK META-ANALYSIS; TREATMENT OUTCOME;

ACUTE KIDNEY INJURY; BAYES THEOREM; CONTRAST MEDIA; HUMANS; NETWORK META-ANALYSIS; TREATMENT OUTCOME;

EID: 84999861909     PISSN: 02726386     EISSN: 15236838     Source Type: Journal    
DOI: 10.1053/j.ajkd.2016.07.033     Document Type: Article

References (60)

1. 1 Nash, K., Hafeez, A., Hou, S., Hospital-acquired renal insufficiency. Am J Kidney Dis 39:5 (2002), 930–936.
2. 2 McCullough, P.A., Contrast-induced acute kidney injury. J Am Coll Cardiol 51:15 (2008), 1419–1428.
3. 3 Mehran, R., Nikolsky, E., Contrast-induced nephropathy: definition, epidemiology, and patients at risk. Kidney Int Suppl 100 (2006), S11–S15.
4. 4 McCullough, P.A., Adam, A., Becker, C.R., et al. Risk prediction of contrast-induced nephropathy. Am J Cardiol 98:6a (2006), 27k–36k.
5. 5 Kelly, A.M., Dwamena, B., Cronin, P., Bernstein, S.J., Carlos, R.C., Meta-analysis: effectiveness of drugs for preventing contrast-induced nephropathy. Ann Intern Med 148:4 (2008), 284–294.
6. 6 Ukaigwe, A., Karmacharya, P., Mahmood, M., et al. Meta-analysis on efficacy of statins for prevention of contrast-induced acute kidney injury in patients undergoing coronary angiography. Am J Cardiol 114:9 (2014), 1295–1302.
7. 7 Jang, J.S., Jin, H.Y., Seo, J.S., et al. Sodium bicarbonate therapy for the prevention of contrast-induced acute kidney injury – a systematic review and meta-analysis. Circ J 76:9 (2012), 2255–2265.
8. 8 Sadat, U., Usman, A., Gillard, J.H., Boyle, J.R., Does ascorbic acid protect against contrast-induced acute kidney injury in patients undergoing coronary angiography: a systematic review with meta-analysis of randomized, controlled trials. J Am Coll Cardiol 62:23 (2013), 2167–2175.
9. 9 Ades, A.E., Sculpher, M., Sutton, A., et al. Bayesian methods for evidence synthesis in cost-effectiveness analysis. Pharmacoeconomics 24:1 (2006), 1–19.
10. 10 Song, F., Altman, D.G., Glenny, A.M., Deeks, J.J., Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses. BMJ, 326(7387), 2003, 472.
11. 11 Lu, G., Ades, A.E., Combination of direct and indirect evidence in mixed treatment comparisons. Stat Med 23:20 (2004), 3105–3124.
12. 12 Leucht, S., Cipriani, A., Spineli, L., et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet 382:9896 (2013), 951–962.
13. 13 Tu, B., Rich, B., Labos, C., Brophy, J.M., Coronary revascularization in diabetic patients: a systematic review and Bayesian network meta-analysis. Ann Intern Med 161:10 (2014), 724–732.
14. 14 Wu, H.Y., Huang, J.W., Lin, H.J., et al. Comparative effectiveness of renin-angiotensin system blockers and other antihypertensive drugs in patients with diabetes: systematic review and Bayesian network meta-analysis. BMJ, 347, 2013, f6008.
15. 15 Moher, D., Liberati, A., Tetzlaff, J., Altman, D.G., Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ, 339, 2009, b2535.
16. 16 Higgins, J.P.T., Green, S., Cochrane Handbook for Systematic Reviews of Interventions, Version 5.1.0. 2011, John Wiley & Sons, Chichester.
17. 17 Harjai, K.J., Raizada, A., Shenoy, C., et al. A comparison of contemporary definitions of contrast nephropathy in patients undergoing percutaneous coronary intervention and a proposal for a novel nephropathy grading system. Am J Cardiol 101:6 (2008), 812–819.
18. 18 Thomsen, H.S., Morcos, S.K., Contrast media and the kidney: European Society of Urogenital Radiology (ESUR) guidelines. Br J Radiol 76:908 (2003), 513–518.
19. 19 Ribichini, F., Graziani, M., Gambaro, G., et al. Early creatinine shifts predict contrast-induced nephropathy and persistent renal damage after angiography. Am J Med 123:8 (2010), 755–763.
20. 20 Roseman, M., Milette, K., Bero, L.A., et al. Reporting of conflicts of interest in meta-analyses of trials of pharmacological treatments. JAMA 305:10 (2011), 1008–1017.
21. 21 Warn, D.E., Thompson, S.G., Spiegelhalter, D.J., Bayesian random effects meta-analysis of trials with binary outcomes: methods for the absolute risk difference and relative risk scales. Stat Med 21:11 (2002), 1601–1623.
22. 22 Cornell, J.E., Mulrow, C.D., Localio, R., et al. Random-effects meta-analysis of inconsistent effects: a time for change. Ann Intern Med 160:4 (2014), 267–270.
23. 23 Brooks, S.P., Gelman, A., General methods for monitoring convergence of iterative simulations. J Comput Graph Stat 7:4 (1998), 434–455.
24. 24 Salanti, G., Ades, A.E., Ioannidis, J.P., Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. J Clin Epidemiol 64:2 (2011), 163–171.
25. 25 Bucher, H.C., Guyatt, G.H., Griffith, L.E., Walter, S.D., The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol 50:6 (1997), 683–691.
26. 26 Tu, Y.K., Needleman, I., Chambrone, L., Lu, H.K., Faggion, C.M. Jr., A Bayesian network meta-analysis on comparisons of enamel matrix derivatives, guided tissue regeneration and their combination therapies. J Clin Periodontol 39:3 (2012), 303–314.
27. 27 Salanti, G., Marinho, V., Higgins, J.P., A case study of multiple-treatments meta-analysis demonstrates that covariates should be considered. J Clin Epidemiol 62:8 (2009), 857–864.
28. 28 Dias S, Welton NJ, Sutton AJ, Caldwell DM, Lu G, Ades AE. NICE DSU technical support document 4: inconsistency in networks of evidence based on randomised controlled trials report by the decision support unit. May 2011 (last updated April 2014). http://www.nicedsu.org.uk/TSD4%20Inconsistency.final.15April2014.Pdf. Accessed February 12, 2015.
29. 29 Dias, S., Welton, N.J., Caldwell, D.M., Ades, A.E., Checking consistency in mixed treatment comparison meta-analysis. Stat Med 29:7-8 (2010), 932–944.
30. 30 Subramaniam, R.M., Suarez-Cuervo, C., Wilson, R.F., et al. Effectiveness of prevention strategies for contrast-induced nephropathy: a systematic review and meta-analysis. Ann Intern Med 164:6 (2016), 406–416.
31. 31 Xinwei, J., Xianghua, F., Jing, Z., et al. Comparison of usefulness of simvastatin 20 mg versus 80 mg in preventing contrast-induced nephropathy in patients with acute coronary syndrome undergoing percutaneous coronary intervention. Am J Cardiol 104:4 (2009), 519–524.
32. 32 Patti, G., Ricottini, E., Nusca, A., et al. Short-term, high-dose atorvastatin pretreatment to prevent contrast-induced nephropathy in patients with acute coronary syndromes undergoing percutaneous coronary intervention (from the ARMYDA-CIN [Atorvastatin for Reduction of Myocardial Damage During Angioplasty–Contrast-Induced Nephropathy] trial). Am J Cardiol 108:1 (2011), 1–7.
33. 33 Ozhan, H., Erden, I., Ordu, S., et al. Efficacy of short-term high-dose atorvastatin for prevention of contrast-induced nephropathy in patients undergoing coronary angiography. Angiology 61:7 (2010), 711–714.
34. 34 Quintavalle, C., Fiore, D., De Micco, F., et al. Impact of a high loading dose of atorvastatin on contrast-induced acute kidney injury. Circulation 126:25 (2012), 3008–3016.
35. 35 Giacoppo, D., Capodanno, D., Capranzano, P., Aruta, P., Tamburino, C., Meta-analysis of randomized controlled trials of preprocedural statin administration for reducing contrast-induced acute kidney injury in patients undergoing coronary catheterization. Am J Cardiol 114:4 (2014), 541–548.
36. 36 Zhang, B.C., Li, W.M., Xu, Y.W., High-dose statin pretreatment for the prevention of contrast-induced nephropathy: a meta-analysis. Can J Cardiol 27:6 (2011), 851–858.
37. 37 Li, Y., Liu, Y., Fu, L., Mei, C., Dai, B., Efficacy of short-term high-dose statin in preventing contrast-induced nephropathy: a meta-analysis of seven randomized controlled trials. PLoS One, 7(4), 2012, e34450.
38. 38 Zhang, T., Shen, L.H., Hu, L.H., He, B., Statins for the prevention of contrast-induced nephropathy: a systematic review and meta-analysis. Am J Nephrol 33:4 (2011), 344–351.
39. 39 Leoncini, M., Toso, A., Maioli, M., Tropeano, F., Villani, S., Bellandi, F., Early high-dose rosuvastatin for contrast-induced nephropathy prevention in acute coronary syndrome: results from the PRATO-ACS Study (Protective Effect of Rosuvastatin and Antiplatelet Therapy On contrast-induced acute kidney injury and myocardial damage in patients with Acute Coronary Syndrome). J Am Coll Cardiol 63:1 (2014), 71–79.
40. 40 Han, Y., Zhu, G., Han, L., et al. Short-term rosuvastatin therapy for prevention of contrast-induced acute kidney injury in patients with diabetes and chronic kidney disease. J Am Coll Cardiol 63:1 (2014), 62–70.
41. 41 Mehran, R., Aymong, E.D., Nikolsky, E., et al. A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation. J Am Coll Cardiol 44:7 (2004), 1393–1399.
42. 42 Haller, C., Hizoh, I., The cytotoxicity of iodinated radiocontrast agents on renal cells in vitro. Invest Radiol 39:3 (2004), 149–154.
43. 43 John, S., Schneider, M.P., Delles, C., Jacobi, J., Schmieder, R.E., Lipid-independent effects of statins on endothelial function and bioavailability of nitric oxide in hypercholesterolemic patients. Am Heart J, 149(3), 2005, 473.
44. 44 Kaesemeyer, W.H., Caldwell, R.B., Huang, J., Caldwell, R.W., Pravastatin sodium activates endothelial nitric oxide synthase independent of its cholesterol-lowering actions. J Am Coll Cardiol 33:1 (1999), 234–241.
45. 45 Laufs, U., Liao, J.K., Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase. J Biol Chem 273:37 (1998), 24266–24271.
46. 46 Ridker, P.M., Rifai, N., Clearfield, M., et al. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med 344:26 (2001), 1959–1965.
47. 47 Wagner, A.H., Kohler, T., Ruckschloss, U., Just, I., Hecker, M., Improvement of nitric oxide-dependent vasodilatation by HMG-CoA reductase inhibitors through attenuation of endothelial superoxide anion formation. Arterioscler Thromb Vasc Biol 20:1 (2000), 61–69.
48. 48 Sketch, M.H. Jr., Whelton, A., Schollmayer, E., et al. Prevention of contrast media-induced renal dysfunction with prostaglandin E1: a randomized, double-blind, placebo-controlled study. Am J Ther 8:3 (2001), 155–162.
49. 49 Katholi, R.E., Taylor, G.J., McCann, W.P., et al. Nephrotoxicity from contrast media: attenuation with theophylline. Radiology 195:1 (1995), 17–22.
50. 50 Kapoor, A., Kumar, S., Gulati, S., Gambhir, S., Sethi, R.S., Sinha, N., The role of theophylline in contrast-induced nephropathy: a case-control study. Nephrol Dial Transplant 17:11 (2002), 1936–1941.
51. 51 Dai, B., Liu, Y., Fu, L., Li, Y., Zhang, J., Mei, C., Effect of theophylline on prevention of contrast-induced acute kidney injury: a meta-analysis of randomized controlled trials. Am J Kidney Dis 60:3 (2012), 360–370.
52. 52 Upton, R.A., Pharmacokinetic interactions between theophylline and other medication (part II). Clin Pharmacokinet 20:2 (1991), 135–150.
53. 53 Upton, R.A., Pharmacokinetic interactions between theophylline and other medication (part I). Clin Pharmacokinet 20:1 (1991), 66–80.
54. 54 Fishbane, S., N-Acetylcysteine in the prevention of contrast-induced nephropathy. Clin J Am Soc Nephrol 3:1 (2008), 281–287.
55. 55 Brown, J.R., Block, C.A., Malenka, D.J., O'Connor, G.T., Schoolwerth, A.C., Thompson, C.A., Sodium bicarbonate plus N-acetylcysteine prophylaxis: a meta-analysis. JACC Cardiovasc Interv 2:11 (2009), 1116–1124.
56. 56 Trinquart, L., Attiche, N., Bafeta, A., Porcher, R., Ravaud, P., Uncertainty in treatment rankings: reanalysis of network meta-analyses of randomized trials. Ann Intern Med 164:10 (2016), 666–673.
57. 57 Markota, D., Markota, I., Starcevic, B., Tomic, M., Prskalo, Z., Brizic, I., Prevention of contrast-induced nephropathy with Na/K citrate. Eur Heart J 34:30 (2013), 2362–2367.
58. 58 Erol, T., Tekin, A., Katircibasi, M.T., et al. Efficacy of allopurinol pretreatment for prevention of contrast-induced nephropathy: a randomized controlled trial. Int J Cardiol 167:4 (2013), 1396–1399.
59. 59 Liu, W.J., Zhang, B.C., Guo, R., Wei, Y.D., Li, W.M., Xu, Y.W., Renoprotective effect of alprostadil in combination with statins in patients with mild to moderate renal failure undergoing coronary angiography. Chin Med J (Engl) 126:18 (2013), 3475–3480.
60. 60 Thompson, S.G., Higgins, J., How should meta-regression analyses be undertaken and interpreted?. Stat Med 21:11 (2002), 1559–1573.